Response rates, survival, and chemotherapy trials

被引:38
作者
Pazdur, R [1 ]
机构
[1] US FDA, Ctr Drug Evaluat & Res, Div Oncol Drug Prod, Rockville, MD 20857 USA
关键词
D O I
10.1093/jnci/92.19.1552
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:1552 / 1553
页数:2
相关论文
共 7 条
[1]   Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis [J].
Buyse, M ;
Thirion, P ;
Carlson, RW ;
Burzykowski, T ;
Molenberghs, G ;
Piedbois, P .
LANCET, 2000, 356 (9227) :373-378
[2]  
Buyse M, 1996, STAT MED, V15, P2797, DOI 10.1002/(SICI)1097-0258(19961230)15:24<2797::AID-SIM290>3.0.CO
[3]  
2-V
[4]   A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer [J].
Chen, TT ;
Chute, JP ;
Feigal, E ;
Johnson, BE ;
Simon, R .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (19) :1601-1607
[5]  
JOHNSON JR, 1985, CANCER TREAT REP, V69, P1155
[6]  
*US FDA, 1966, REINV REG CANC DRUGS
[7]   COMPARING SURVIVAL OF RESPONDERS AND NONRESPONDERS AFTER TREATMENT - A POTENTIAL SOURCE OF CONFUSION IN INTERPRETING CANCER CLINICAL-TRIALS [J].
WEISS, GB ;
BUNCE, H ;
HOKANSON, JA .
CONTROLLED CLINICAL TRIALS, 1983, 4 (01) :43-52